The promising anticancer drug 3-bromopyruvate is metabolized through glutathione conjugation which affects chemoresistance and clinical practice: An evidence-based view

This publication has 79 references indexed in Scilit:

• 3-Bromopyruvate: A novel antifungal agent against the human pathogen Cryptococcus neoformans
  Biochemical and Biophysical Research Communications, 2013
• Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells
  PLOS ONE, 2011
• Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment
  Biochemical Journal, 2011
• Recruitment of genes and enzymes conferring resistance to the nonnatural toxin bromoacetate
  Proceedings of the National Academy of Sciences, 2010
• Potential cytotoxic effect of hydroxypyruvate produced from D-serine by astroglial D-amino acid oxidase
  The Journal of Biochemistry, 2010
• 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines
  Biochemical and Biophysical Research Communications, 2010
• Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3‐bromopyruvate
  Cancer, 2009
• Inactivation of H+-vacuolar ATPase by the energy blocker 3-bromopyruvate, a new antitumour agent
  Life Sciences, 2006
• Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP
  Biochemical and Biophysical Research Communications, 2004
• Reactivity of the thiol groups of Escherichia coli phosphofructo-1-kinase
  Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1988